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Abstract 
Study objectives and methods To measure the prevalence of, and factors 
associated with, left ventricular (LV) dysfunction in SSc, we first queried the  
EUSTAR database. In a second phase, we performed a case-control study of a 
patient subset, to further identify independent factors associated with LV dysfunction 
by simple and multiple regression.  
Results Among 7,073 patients, 383 (5.4%) had a LV ejection fraction (EF) <55%. By 
multiple regression analysis, age, sex, diffuse cutaneous disease, disease duration, 
digital ulcerations, renal and muscle involvement, disease activity score, pulmonary 
fibrosis and pulmonary arterial hypertension (PAH) were associated with LV 
dysfunction. In a second phase, 129 SSc patients with LVEF <55% were compared 
with 256 SSc patients with normal LVEF. Male sex (OR 3.48; 95% CI1.74-6.98), age 
(OR 1.03; 95% CI 1.01-1.06), digital ulcerations (OR 1.91; 95% CI 1.05-3.50), 
myositis (OR 2.88; 95% CI 1.15-7.19), and calcium channel blockers (CCB) use (OR 
0.41; 95% CI 0.22-0.74) were independent factors associated with LV dysfunction.   
Conclusion The prevalence of LV dysfunction in SSc is 5.4%. Age, male gender, 
digital ulcerations, myositis and lung involvement are independently associated with 
increased prevalence of LV dysfunction. Conversely, CCB use may appear as 
protective.  
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Introduction  
 The prevalence of primary myocardial involvement by systemic sclerosis 
(SSc) has been subject to particular attention in recent years (1-3). It appears that 
once clinically apparent, cardiac involvement has a very poor prognosis (4-7). While 
the overall long-term prognosis of patients with SSc seems to have improved in 
recent years, the proportion of deaths due to heart disease has not changed 
significantly (7). The objective of this study was to precisely measure the prevalence 
of LV dysfunction ascertained by standard echocardiography, and to identify factors 
associated with a depressed LV ejection fraction (EF). 
  
Patient population and methods 
We first queried the EUSTAR database that has been described previously in details 
(8). LVEF was measured echocardiographically at each participating center, using 
Simpson’s method: LVEF was classified as depressed if <55% or <50%.  In a 
second phase, we performed a case-control study of a patient subset, to further 
identify independent factors associated with LV dysfunction by simple and multiple 
regression including parameters not registered in the EUSTAR database. Methods 
and statistical analysis details are available in supplemental file 1.   
 
Results   
By April 2008, 7,283 patients had been enrolled. Since neither LVEF nor the 
presence of LV dysfunction was recorded in 209, this analysis includes data 
collected in 7,073 patients (mean age 56±14 years, 981 [13.9%] men). A total of 383 
patients had a reduced LVEF corresponding to a 5.4% prevalence. The main 
characteristics of patients with versus those without LV dysfunction are shown in 
table 1.  
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Table 1:  Characteristics of patients presenting with SSc and depressed versus 
normal left ventricular ejection fraction 
 Left ventricular ejection 
fraction 
 
 Depressed  
(n=383) 
Normal  
(n=6,690) 
P  
Age, y (means ± SD) 61.3±13.4 56.1±13.7 <0.001 
Men/women (%) 23/77 13/87 <0.001 
Disease duration, y 12.0±9.7 9.6±7.8 <0.001 
Cutaneous subtype;  
Diffuse (%) 
 
47.5 
 
32.0 <0.001 
Friction rub (%) 19.2 10.8 <0.001 
Synovitis (%) 23.3 16.2 <0.001 
Raynaud’ syndrome (%) 96.9 95.4 0.181 
Digital ulceration (%) 52.4 30.5 <0.001 
Muscle weakness (%) 47.9 25.9 <0.001  
Pulmonary fibrosis (plain X-ray) (%) 56.9 35.5 <0.001 
Elevated systolic pulmonary artery pressure (%)  50.7 18.7 <0.001 
Palpitation (%) 48.9 23.1 <0.001 
Conduction abnormality on electrocardiogram (%) 33.3 9.1 <0.001 
Renal crisis (%) 8.2 1.9 <0.001 
Positive anti-nuclear antibodies (%) 92.4 91.9 0.736 
Positive anti-topoisomerase-1 antibodies (%) 37.5 32.1 0.030 
Positive anti-centromere antibodies (%) 25.7 34.5 0.001 
Elevated creatine–phosphokinase (%) 11.4 8.0 0.019 
Elevation of acute phase reactants (%) 50.0 29.4 <0.001 
Proteinuria (%) 15.3 5.45 <0.001 
Active disease according to European score (%) 51.1 29.1 <0.001 
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Table 2 shows the ORs and 95% CI of associated factors with LV dysfunction.  
 
Table 2: Factors significantly associated with a reduced left ventricular 
ejection fraction 
 Univariate analysis Multivariate analysis 
 OR 95% CI P OR 95% CI P 
Age 1.02 1.04-10.2 <0.001 1.03 1.02-1.04 <0.001 
Male gender 2.0 1.6-2.6 <0.001 1.98 1.46-2.68 <0.001 
Disease duration, years 1.04 1.02-1.05 <0.001 1.03 1.02-1.04 <0.001 
Diffuse cutaneous subtype 1.92 1.56-2.36 <0.001 1.38 1.06-1.81 0.018 
Presence of friction rubs 1.96 1.50-2.55 <0.001   NS 
Presence of synovitis 1.57 1.23-2.01 <0.003   NS 
Presence of digital ulceration 2.51 2.03-3.01 <0.001 2.05 1.59-2.64 <0.001 
Presence of muscle weakness 2.62 2.13-3.24 <0.001 1.86 1.44-2.39 <0.001 
Pulmonary fibrosis 2.39 1.94-2.95 <0.001 1.33 1.02-1.72 0.034 
Renal crisis  4.70 3.12-7.01 <0.001 3.60 2.14-6.07 <0.001 
Positive anti-topoisomerase-1 antibodies 1.27 1.02-1.58 0.030   NS 
Positive anti-centromere antibodies 0.66 0.52-0.83 <0.001   NS 
Elevation of acute phase reactants 2.40 1.95-2.97 <0.001   NS 
Active disease (European score) 
  Elevated systolic pulmonary artery pressure 
2.55 2.06-316 <0.001 1.42 
2.63 
1.09-1.86 
2.03-3.41 
0.011 
<0.001 
 
It is noteworthy that men presenting with diffuse cutaneous SSc and active or 
past digital ulcerations, representing 203 patients (2.8%) in this study, were at 
particularly high risk of LV dysfunction (OR 3.2; 95% CI 2.1-4.9).  
 
Case-control analysis 
The second phase of the study included 385 patients including 129 with LVEF <55% 
and 256 controls. Diffuse cutaneous SSc was present in 145 patients, pulmonary 
fibrosis in 176, past or active digital ulcer in 204, and histories of renal crisis in 6 
patients. Echocardiography revealed the presence of a systolic PAP >40 mmHg in 
114 patients, of whom 34 had pre-capillary PAH confirmed by cardiac 
catheterization. Associated factors with reduced LVEF according to univariate and 
multivariate analyses are represented in table 3. 
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Table 3: Characteristics of SSc patients with and without abnormal left ventricular ejection fraction included in the nested 
case-control study.  
 Left ventricular ejection fraction  Multivariate analysis (stepwise regression) 
 Reduced  (n=129) Normal (n=256) P  OR 95% CI P 
Age, y 59.8±12.7 56.2±12.8 0.008 1.03 1.01-1.06 0.008 
Men/women (%) 33 / 67 12 / 88 <0.001 3.48 1.74-6.98 <0.001 
Disease duration, mo (1st non-Raynaud symptom) 68.9±129.7 51.3±68.8 0.081   NS 
Diffuse/limited cutaneous subtype (%) 45/55 34 / 66 0.036   NS 
Smoking (past or present) (%) 21.1 11.1 0.009   NS 
Systemic hypertension (%) 34.9 27.7 0.155   NS 
Body mass index 23.6±4.6 24.7±4.4 0.031   NS 
Diabetes (%) 5.5 4.3 0.615   NS 
Presence of digital ulceration (%) 61.7 50 0.038 1.91 1.05-3.50 0.035 
Presence of pulmonary fibrosis (%) 59.3 45.7 0.016   NS 
Forced vital capacity 84.5±23.6 94.1±21.1 <0.001 0.98 0.96-0.99 0.001 
Lung carbon monoxide diffusion; DLCO/VA 66.6±22.2 77.4±20.2 <0.001   NS 
Echo sPAP 38.2±17.9 30.2±11.7 <0.001   NS 
Pre-capillary PAH (%) 14.7 7.6 0.041   NS 
Myositis (%) 12.7 5.4 0.013 2.88 1.15-7.19 0.024 
Renal crisis (%) 5 2.5 0.227   NS 
Positive anti-topoisomerase-1 antibodies (%) 31.2 37.8 0.206   NS 
Positive anti-centromere antibodies (%) 30.2 31.4 0.802   NS 
Use of CCB, past or present (%) 51.9 68.7 0.001 0.41 0.22-0.74 0.004 
CCB for >12 months (%) 45.7 60.2 0.009   NA 
Use of low dose prednisone (≤10 mg/d) 43.7 34.9 0.095   NS 
Use of immunosuppressors (%) 48.1 42.6 0.313   NS 
Use of endothelin antagonists (%) 16.3 9.8 0.065   NS 
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We conducted similar analyses for LVEF <45% (n=36) that confirmed the above 
results (supplemental file 1). 
 
Discussion 
The main observations made in this analysis were i) a 5.4% prevalence of LV 
dysfunction, ii) the identification of age, male gender, myositis, digital ulcers, lung 
involvement and absence of previous CCB treatment as associated factors with 
reduced LVEF.  
Large studies that evaluate LV dysfunction are sparse. In a multicenter study 
of PAH, a post hoc analysis identified only 8 of 570 SSc patients (1.4%) with LVEF 
<45% (2).The EUSTAR database offers a unique opportunity to study the 
complications of SSc. The 5.4% prevalence of reduced LVEF measured in the first 
phase of our study is concordant with the 7.2% prevalence among patients with 
diffuse SSc, and 5% in patients with limited SSc, observed in the first report from 
EUSTAR (8). Therefore, a depressed LVEF stands among the 4 main manifestations 
of major organ involvement in SSc, together with PAH (9-11), renal crisis (12)  and 
interstitial lung disease.  
The second objective was the identification of factors associated with a 
reduced LVEF. We used a two-step strategy that included 1) an analysis of the entire 
EUSTAR database, allowing the inclusion of robust factors unequivocally pertinent 
considering the large number of patients included, and 2) a nested prospective case-
control study of a subgroup, that includes more data, such as atherosclerosis risk 
factors, drug regimen and the presence of pre-capillary PAH. In order to limit the 
impact of disease duration, a typical contributor to organ dysfunction, we matched 
our two study groups for disease duration. Both analyses confirmed that male 
gender, age, muscle involvement, digital ulceration were independent associated 
factors with LV dysfunction. The association between digital ulcerations and cardiac 
dysfunction may be a manifestation of the diffuse microvascular lesions, which 
characterize the disease (1). The significant association between systolic PAP and 
reduced LVEF observed in the first part of the study should be interpreted with 
caution, since systolic PAP is influenced by LV function, and this is emphasized by 
the lack of independent association with pre-capillary PAH found in the second part 
of our study. In the nested study, except for male gender, typical cardiovascular risk 
factors were not associated with a reduced LVEF, an observation concordant with 
the prior demonstration of a predominant contribution of microangiopathy, versus the 
controversial results regarding that of atherosclerosis, in the development of primary 
myocardial involvement in SSc (1). Another important finding of the nested study 
was the markedly lower proportion of patients with reduced LVEF who had been 
previously treated with CCB. This is concordant with previous short-term studies (1). 
In addition, Steen et al. reported that patients presenting with PAH were significantly 
less often treated with CCB than patients without PAH (13) and, in another study, the 
development of digital ulcers was also delayed by vasodilator therapy (14). 
Altogether, these observations suggest that CCB may protect against microvascular 
complicationst. Pending the results of long-term prospective study, the broad use of 
CCB in patients with SSc, unless contraindicated, should be strongly considered. 
Our study is limited by its observational design and since we studied patients with a 
LVEF <55%, which has not been associated with an increased mortality in patients 
with SSc, our results do not apply to mortality. We expect the prospective follow-up 
that is ongoing to enable the identification of predictors of LV dysfunction and 
outcome in SSc patients with mildly decreased LVEF. 
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METHODS 
EUSTAR Registry 
The European League Against Rheumatism (EULAR) Scleroderma Trials And 
Research (EUSTAR) MYOCARDIUM study is a two-phase program based on data 
collected in patients with SSc included in the EUSTAR registry. The structure and 
Minimal Essential Dataset (MEDS) of the EUSTAR database have been described 
previously in details (8). Briefly, since 2004, 150 participating medical centers entered 
consecutive patients in a registry, and all data in a specific database, which was 
locked for this study in April 2008. The registry includes demographic information, 
classification criteria, and a detailed clinical evaluation of SSc, that has been 
described elsewhere (8). Clinical variables include distinction of the cutaneous subset 
of the disease, disease duration, detection of antibodies and acute phase reactants, 
disease activity score, presence of active or past digital ulcerations, and the presence 
of renal, muscle, gastro-intestinal, pulmonary and cardiac involvement. 
Atherosclerotic risk factors and drug regimens were not recorded. LVEF was 
measured echocardiographically at each participating center, using Simpson’s 
method. LVEF was classified as depressed if <55% or <50%, depending on the cut-
off value adopted at each echocardiography laboratory. Baseline data collected 
during the first patient visit at a EUSTAR center were analyzed. 
Case-control study 
In a second 18-month phase, EUSTAR centers identified in the first step as having 
included patients with reduced LVEF were asked to include a) SSc patients identified 
as having echocardiographic LVEF <55% in the first phase and consecutively re-
assessed in their respective center together with b) patients with SSc with normal 
LVEF (controls) who were enrolled in a 1:2 ratio in a nested case-control study, at the 
time of their next visit. Control patients 1) were entered in the registry either 
simultaneously or immediately after a patient with reduced LVEF, and 2) were 
matched for disease duration (±1 year). The data collected included te items of the 
EUSTAR registry, atherosclerosis risk factors, detailed pulmonary function tests, and 
drug regimen, including corticosteroids, calcium channel blockers (CCB) and 
endothelin antagonists prescribed for >3 months. Angiotensin converting enzyme 
inhibitors were only considered if prescribed before the occurrence of LV dysfunction. 
When pulmonary arterial hypertension (PAH) was suspected, catheterization was 
recommended to 1) confirm its presence, defined as a mean pulmonary arterial 
pressure (PAP) >25mmHg, and 2) identify patients with pre-capillary PAH. Myositis 
was defined by any clinical symptom (myalgia with or without weakness) together 
with an elevation in creatine phosphokinases values in the absence of any other 
potential explanation. 
All patients included in either database granted their informed consent to participate, 
and the research program was approved by all appropriate institutional ethics 
committees. 
 
 
STATISTICAL ANALYSES 
Data were expressed as means ± standard deviation for continuous variables and 
numbers and percentages for categorical variables. From the EUSTAR registry, we 
first assessed the prevalence of LV dysfunction. To identify all potential factors 
associated with the existence of LV dysfunction, SSc patients with LV dysfunction 
were compared with SSc patients having normal LVEF using Student’s t-test for 
 group.bmj.com on March 15, 2011 - Published by ard.bmj.comDownloaded from 
comparisons of normally distributed continuous variables, and chi-square test for 
differences in frequency. Odds ratio (OR) estimates and 95% confidence intervals 
from logistic regression were then calculated. Due to multiple tests, p-values between 
0.01 and 0.05 should be interpreted with caution. In order to identify independent 
factors associated with LV dysfunction, all variables with p<0.10 univariately, were 
entered as covariates in stepwise regression analysis. A similar protocol was used to 
identify associated factors with reduced LVEF in the second phase of the study 
(nested case-control). All analyses were performed with the STATA® statistical 
software, version 9.2 (StataCorp LP, College Station, TX). A p value <0.05 was 
considered statistically significant.  
 
RESULTS 
Although not planned by the original study protocol, we conducted multivariate 
analyses for associated factors with LVEF <45% (n=36) (4). Male gender (OR 2.62; 
95% CI 1.17-5.89), diffuse SSc (OR 2.50; 95% CI 1.14-5.50) and absence of 
treatment with a CCB (OR 0.41; 95% CI 0.19-0.89) were associated by multiple 
variable analysis, and a trend was observed for digital ulcers (OR 2.06; 95% CI 0.89-
4.79, p=0.09). 
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